Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
The coverage policy includes serial testing with Prospera to assess graft status and identify the risk of rejection following a kidney or heart transplant.
- The coverage policy includes serial testing with Prospera to assess graft status and identify the risk of rejection following a kidney or heart transplant.
- “Improving long-term outcomes for this population starts with more accurate and non-invasive tools to identify potential graft issues earlier.”
Natera and its academic partners have published significant peer-reviewed evidence supporting the clinical utility of Prospera. - In addition, Natera has completed enrollment in the PEDAL and MOTR trials.
- These are both multi-site, prospective studies designed to provide novel evidence supporting the clinical utility of Prospera, with expected publication in 2024.